The Evaluation of the Inflammatory Status and Systemic Antioxidant-oxidant Balance of Women with Breast Cancer During Adjuvant Chemotherapy

Overview

Journal Rep Pract Oncol Radiother

Date 2025 Feb 3

PMID 39895965

Authors

Joanna Grupinska

Magdalena Budzyn

Jakub Janowski

Bogna Gryszczynska

Elzbieta Kaja

Jacek J Brzezinski

Ewa Leporowska

Dorota Formanowicz

Witold Kycler

Affiliations

Soon will be listed here.

Abstract

Background: Chemotherapy may cause systemic inflammation. Therefore, reliable markers monitoring inflammation during cancer treatment are intensively investigated. In our study, we analyzed the concentration of high-sensitivity C-reactive protein (hs-CRP) and selected oxidative stress markers, such as malondialdehyde (MDA), glutathione peroxidase activity (GPx), and total antioxidant capacity (TAC), in breast cancer women before and during adjuvant chemotherapy.

Materials And Methods: The study included 90 women with breast cancer stratified according to clinicopathological and anthropometric features. Blood samples were taken before and after two cycles of adjuvant chemotherapy.

Results: During adjuvant chemotherapy, a significant increase in hs-CRP concentration was noticed in the entire group of patients with breast cancer. After division into appropriate groups, a twofold increase in hs-CRP concentration was particularly observed in patients not expressing steroid hormone receptors and those without metastases in regional lymph nodes. A significant rise in hs-CRP was observed in patients with smaller tumor sizes (2 cm ≤) and with a lower stage of disease [I-IIA according to the tumor-node-metastasis (TNM) classification]. Adjuvant chemotherapy resulted in a significant decrease in GPx activity, especially in patients diagnosed with larger (> 2 cm) and more advanced tumors (IIB-IIIC according to the TNM classification), without metastasis in regional lymph nodes, and without HER-2 expression. A significant decrease in glutathione peroxidase (GPx) activity during adjuvant chemotherapy was also observed in patients with abnormal body mass index (BMI) and body fat content. TAC and MDA values remained unchanged in the entire group of patients and individual subgroups during adjuvant chemotherapy.

Conclusion: Our study showed that adjuvant chemotherapy causes systemic inflammation, manifested by increased hs-CRP and altered markers of oxidative stress in the blood of breast cancer patients. The severity of inflammatory processes during adjuvant chemotherapy may depend on specific characteristics of breast cancer and body composition.

References

Kaur R, Rubal , Banipal R, Vashistha R, Dhiman M, Munshi A . Association of elevated levels of C-reactive protein with breast cancer, breast cancer subtypes, and poor outcome. Curr Probl Cancer. 2018; 43(2):123-129. DOI: 10.1016/j.currproblcancer.2018.05.003. View

Xia Y, Shen S, Verma I . NF-κB, an active player in human cancers. Cancer Immunol Res. 2014; 2(9):823-30. PMC: 4155602. DOI: 10.1158/2326-6066.CIR-14-0112. View

Amin K, Mohamed B, El-Wakil M, Ibrahem S . Impact of breast cancer and combination chemotherapy on oxidative stress, hepatic and cardiac markers. J Breast Cancer. 2012; 15(3):306-12. PMC: 3468784. DOI: 10.4048/jbc.2012.15.3.306. View

McClung H, Ptomey L, Shook R, Aggarwal A, Gorczyca A, Sazonov E . Dietary Intake and Physical Activity Assessment: Current Tools, Techniques, and Technologies for Use in Adult Populations. Am J Prev Med. 2018; 55(4):e93-e104. DOI: 10.1016/j.amepre.2018.06.011. View

Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A . Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021; 13(17). PMC: 8428369. DOI: 10.3390/cancers13174287. View

Melnikov F, Botta D, White C, Schmuck S, Winfough M, Schaupp C . Kinetics of Glutathione Depletion and Antioxidant Gene Expression as Indicators of Chemical Modes of Action Assessed in Vitro in Mouse Hepatocytes with Enhanced Glutathione Synthesis. Chem Res Toxicol. 2018; 32(3):421-436. PMC: 7773541. DOI: 10.1021/acs.chemrestox.8b00259. View

Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Tortosa M, Ramirez-Tortosa C, Granados-Principal S, Lorente J . Oxidative stress status in metastatic breast cancer patients receiving palliative chemotherapy and its impact on survival rates. Free Radic Res. 2011; 46(1):2-10. DOI: 10.3109/10715762.2011.635658. View

Zablocka-Slowinska K, Porebska I, Golecki M, Kosacka M, Pawelczyk K, Pawlik-Sobecka L . Total antioxidant status in lung cancer is associated with levels of endogenous antioxidants and disease stage rather than lifestyle factors - preliminary study. Contemp Oncol (Pozn). 2016; 20(4):302-7. PMC: 5032158. DOI: 10.5114/wo.2016.61850. View

Jiang C, Xiu Y, Yu X, Qiao K, Zhang S, Huang Y . Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy. BMC Cancer. 2022; 22(1):1249. PMC: 9717545. DOI: 10.1186/s12885-022-10291-2. View

10.

Shi W, Misra S, Li M, Su J, Chong L, McCuske M . Inflammatory Biomarkers, Hematopoietic Stem Cells, and Symptoms in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy. JNCI Cancer Spectr. 2020; 4(5):pkaa037. PMC: 7583146. DOI: 10.1093/jncics/pkaa037. View

11.

Yang H, Villani R, Wang H, Simpson M, Roberts M, Tang M . The role of cellular reactive oxygen species in cancer chemotherapy. J Exp Clin Cancer Res. 2018; 37(1):266. PMC: 6211502. DOI: 10.1186/s13046-018-0909-x. View

12.

Gennari A, Andre F, Barrios C, Cortes J, de Azambuja E, DeMichele A . ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021; 32(12):1475-1495. DOI: 10.1016/j.annonc.2021.09.019. View

13.

Silvestrini A, Meucci E, Ricerca B, Mancini A . Total Antioxidant Capacity: Biochemical Aspects and Clinical Significance. Int J Mol Sci. 2023; 24(13). PMC: 10341416. DOI: 10.3390/ijms241310978. View

14.

Schauer T, Henriksson A, Strandberg E, Lindman H, Berntsen S, Demmelmaier I . Pre-treatment levels of inflammatory markers and chemotherapy completion rates in patients with early-stage breast cancer. Int J Clin Oncol. 2022; 28(1):89-98. DOI: 10.1007/s10147-022-02255-0. View

15.

Hu J, Urbanic J, Case L, Takita C, Wright J, Brown D . Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population. J Clin Oncol. 2018; 36(24):2473-2482. PMC: 6097833. DOI: 10.1200/JCO.2017.77.1790. View

16.

Seebacher N, Krchniakova M, Stacy A, Skoda J, Jansson P . Tumour Microenvironment Stress Promotes the Development of Drug Resistance. Antioxidants (Basel). 2021; 10(11). PMC: 8615091. DOI: 10.3390/antiox10111801. View

17.

Asegaonkar S, Asegaonkar B, Takalkar U, Advani S, Thorat A . C-Reactive Protein and Breast Cancer: New Insights from Old Molecule. Int J Breast Cancer. 2015; 2015:145647. PMC: 4674617. DOI: 10.1155/2015/145647. View

18.

Barbaresko J, Koch M, Schulze M, Nothlings U . Dietary pattern analysis and biomarkers of low-grade inflammation: a systematic literature review. Nutr Rev. 2013; 71(8):511-27. DOI: 10.1111/nure.12035. View

19.

Erejuwa O, Sulaiman S, Ab Wahab M . Evidence in support of potential applications of lipid peroxidation products in cancer treatment. Oxid Med Cell Longev. 2013; 2013:931251. PMC: 3867858. DOI: 10.1155/2013/931251. View

20.

Gomes Junior A, Correia Jardim Paz M, da Silva L, Carvalho S, Sobral A, Machado K . Serum Oxidative Stress Markers and Genotoxic Profile Induced by Chemotherapy in Patients with Breast Cancer: A Pilot Study. Oxid Med Cell Longev. 2015; 2015:212964. PMC: 4630415. DOI: 10.1155/2015/212964. View